Takeda to acquire late-stage, potential best-in-class, oral allosteric tyk2 inhibitor ndi-034858 from nimbus therapeutics

Osaka, japan & cambridge, mass.--( business wire )--takeda ( tse:4502/nyse:tak ) today announced that it will acquire ndi-034858 from nimbus therapeutics. ndi-034858 is an oral, selective allosteric tyrosine kinase 2 (tyk2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent phase 2b results in psoriasis. when the transaction is complete, ndi-034858 will be known as tak-279.
TAK Ratings Summary
TAK Quant Ranking